Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 309

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

BNT162b2 Vaccine Booster and Mortality Due to Covid-19

Open access
Arbel, Ronen, Hammerman, Ariel, Sergienko, Ruslan, Friger, Michael, Peretz, Alon, Netzer, Doron, Yaron, Shlomit·2021·New England Journal of Medicine
DOI 10.1056/nejmoa2115624
Open this paper in CoChat — free account

Abstract

BACKGROUND: The emergence of the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 and the reduced effectiveness over time of the BNT162b2 vaccine (Pfizer-BioNTech) led to a resurgence of coronavirus disease 2019 (Covid-19) cases in populations that had been vaccinated early. On July 30, 2021, the Israeli Ministry of Health approved the use of a third dose of BNT162b2 (booster) to cope with this resurgence. Evidence regarding the effectiveness of the booster in lowering mortality due to Covid-19 is still needed. METHODS: We obtained data for all members of Clalit Health Services who were 50 years of age or older at the start of the study and had received two doses of BNT162b2 at least 5 months earlier. The mortality due to Covid-19 among participants who received the booster during the study period (booster group) was compared with that among participants who did not receive the booster (nonbooster group). A Cox proportional-hazards regression model with time-dependent covariates was used to estimate the association of booster status with death due to Covid-19, with adjustment for sociodemographic factors and coexisting conditions. RESULTS: A total of 843,208 participants met the eligibility criteria, of whom 758,118 (90%) received the booster during the 54-day study period. Death due to Covid-19 occurred in 65 participants in the booster group (0.16 per 100,000 persons per day) and in 137 participants in the nonbooster group (2.98 per 100,000 persons per day). The adjusted hazard ratio for death due to Covid-19 in the booster group, as compared with the nonbooster group, was 0.10 (95% confidence interval, 0.07 to 0.14; P<0.001). CONCLUSIONS: Participants who received a booster at least 5 months after a second dose of BNT162b2 had 90% lower mortality due to Covid-19 than participants who did not receive a booster.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2115624

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 8

  1. 10.1016/S0140-6736(21)01358-1 · DOI · Paper page
  2. Goldberg Y Mandel M Bar-On YM et al. Waning immunity of the BNT162b2 vaccine: a nationwide study from Israel. August 30 2021 (https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v1). preprint. · DOI
  3. 10.1056/NEJMc2112981 · DOI
  4. 10.1016/S0140-6736(21)02046-8 · DOI
  5. 10.1371/journal.pone.0247461 · DOI · Paper page
  6. 10.21037/atm.2018.02.12 · DOI · Paper page
  7. Bar-On YM Goldberg Y Mandel M et al. Protection across age groups of BNT162b2 vaccine booster against Covid-19. October 7 2021 (https://www.medrxiv.org/content/10.1101/2021.10.07.21264626v1). preprint. · DOI
  8. 10.1136/bmj.n971 · doi:10.1136/bmj.n971

Cited by

See all 309

Metadata

Authors
Arbel, R., Hammerman, A., Sergienko, R., Friger, M., Peretz, A., Netzer, D., & Yaron, S.
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2021-12-23
Volume
385
Issue
26
Pages
2413-2420
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa2115624
OpenAlex
W4200039328
Cited by
309
References
11
FWCI
21.03
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BNT162b2 Vaccine Booster and Mortality Due to Covid-19. https://app.cochat.ai/papers/10.1056/nejmoa2115624
The paper
Arbel, R., Hammerman, A., Sergienko, R., Friger, M., Peretz, A., Netzer, D., & Yaron, S. (2021). BNT162b2 Vaccine Booster and Mortality Due to Covid-19. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2115624

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.